TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances
TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances作者机构:Department of HematologyTianjin Medical University General Hospital
出 版 物:《Clinical oncology and cancer researeh》 (Cancer Biol. Med.)
年 卷 期:2012年第9卷第1期
页 面:34-37页
核心收录:
学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金:supported by grants from the National Natural Science Foundation of China(No.30971286, 30971285,81170472) Chinese Medical Association of Molecular Biology Clinical Application Research Special Funds(No.CAMB042010) The"Eleventh Five-year Plan"National Science and Technology Support Plan(No. 2008BA161B00) Health Industry Research Special Project (No.201002024)
主 题:myelodysplastic syndrome TET2 gene clinical features
摘 要:Objective To investigate the expression of TET2 mRNA and protein in the bone marrow mononuclear cells (BMMNC) of patients with myelodysplastic syndrome (MDS) and its clinical significance. Methods The expression of TET2 mRNA and protein in bone marrow mononuclear cells (BMMNC) of 32 patients with MDS and 20 healthy donors was examined by qPCR and Western blot. Results The expression of TET2 mRNA in BMMNC was down-regulated in MDS patients compared with the donor group [(0.41±0.28)% vs. (1.07±0.56)%] (P〈0.001). Compared with lower expression group (TET2〈0.4) [(6.53±6.17)%], patients with higher expression of TET2 ≥0.4) presented significantly lower proportion of bone marrow blasts [(1.21±1.56)%1 (P〈0.05). The expression of TET2 mRNA in BMMNC of MDS patients was inversely correlated with malignant clone burden (t=--0.398, P〈0.05) and IPSS r=-0.412, P〈0.05). The expression of TET2 protein was down-regulated in MDS patients compared with that in the donor group. Conclusions The mRNA and protein expression of TET2 in BMMNC of MDS patients is decreased, which might be useful as an important parameter for the evaluation of MDS clone burden.